Compare iShares Russell 2000 ETF (IWM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Zoetis Inc — how do they compare? iShares Russell 2000 ETF trades at $296.05, while Zoetis Inc trades at $75.16 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while iShares Russell 2000 ETF pays none, and iShares Russell 2000 ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| IWM | ZTS | |
|---|---|---|
52-Week High | $300.45 | $156.76 |
52-Week Low | $214.95 | $71.91 |
Market Cap | — | $31.95B |
Sector | — | Health |
Enterprise Value | — | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM, the iShares Russell 2000 ETF, trades at $292.34, down 0.6% on the day. Technical indicators are mixed with a neutral overall signal, while moving averages show a bullish bias. The ETF has seen strong institutional inflows, with firms like AIA Group and Allspring Global Investments increasing their holdings significantly in Q1 2026 (SEC 13F filings, July 2026). Small-cap stocks have outperformed large-caps year-to-date, with the Russell 2000 up approximately 20% in 2026 (24/7 Wall Street, July 17, 2026).
The outlook for IWM hinges on continued small-cap strength, which is sensitive to interest rates and economic growth. While recent performance is robust, risks include higher volatility versus large-caps and potential Fed policy shifts. Analyst sentiment is divided, with some highlighting valuation concerns versus broader market ETFs.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
